Double-blind, randomised, placebo-controlled phase I trial with single-ascending and multiple-ascending dose to evaluate safety and pharmacokinetics of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) compared to immediate-release nicotinamide and placebo in healthy subjects and in patients with inflammatory bowel diseases.
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Treatment-Emergent Adverse Events [Safety and Tolerability]
Timeframe: up to 60 days
Treatment-Emergent Serious Adverse Events [Safety and Tolerability]
Timeframe: up to 60 days
Haemoglobin
Timeframe: up to 60 days
White blood cells
Timeframe: up to 60 days
Blood creatinine
Timeframe: up to 60 days
Blood urea
Timeframe: up to 60 days
Blood uric acid
Timeframe: up to 60 days
Glomerular filtration rate
Timeframe: up to 60 days
Blood ALT
Timeframe: up to 60 days
Blood AST
Timeframe: up to 60 days
Blood GGT
Timeframe: up to 60 days